Fox Run Management’s Immunome IMNM Stock Holding History

Fox Run Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,220	Closed	-$203K	–	1029
2025 Q1	$203K	Buy	+30,220	New	+$290K	0.03%	796

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fox Run Management's IMNM Position: Q2 2025 in Review

Fox Run Management sold out of Immunome (IMNM) in Q2 2025, closing a stake of 30,220 shares — an estimated $203K sold.

Fox Run Management first reported a position in IMNM in Q1 2025 and held it in 1 quarter. The position peaked at $203K in Q1 2025. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

Fox Run Management reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 30,220 Immunome shares in Q2 2025, an estimated $203K.
Fox Run Management first reported a position in Immunome in Q1 2025 and held it in 1 quarter.
Fox Run Management's Immunome position peaked at $203K in Q1 2025.
142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.